IQVIA Holdings Inc.: 10-K Risk Factor Changes

2026 vs 2025  ·  SEC EDGAR  ·  2026-05-22
Other years: 2025 vs 2024 · 2024 vs 2023
⚠ AI-Generated

The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.

IQVIA made substantive modifications to six existing risk factors while maintaining 56 unchanged disclosures and adding no new risks. The most significant revisions involved Client Risks, technology acquisition and deployment challenges, and data protection and privacy compliance obligations, indicating refinements to how IQVIA characterizes risks related to client relationships, digital infrastructure, and regulatory requirements rather than fundamental shifts in its risk profile.

✓ Deterministic extraction — no AI-generated data

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

0
New Risks
0
Removed
6
Modified
56
Unchanged
🟡 Modified

Client Risks

high match confidence

Sentence-level differences:

Current (2026):

•Consolidation in the industries in which our clients operate may reduce the volume of services purchased by consolidated clients following an acquisition or merger. •We may be adversely affected by client or therapeutic concentration. •Our relationships with existing or…

Read full text

•Consolidation in the industries in which our clients operate may reduce the volume of services purchased by consolidated clients following an acquisition or merger. •We may be adversely affected by client or therapeutic concentration. •Our relationships with existing or potential clients who are in competition with each other may adversely impact the degree to which other clients or potential clients use our services. •There is a risk that we may initiate a clinical trial for a client, and then the client becomes unwilling or unable to fund the completion of the clinical trial, and we may be ethically bound to complete or wind down the clinical trial at our own expense. 18 18 18

View prior text (2025)

•Consolidation in the industries in which our clients operate may reduce the volume of services purchased by consolidated clients following an acquisition or merger. •We may be adversely affected by client or therapeutic concentration. •Our relationships with existing or potential clients who are in competition with each other may adversely impact the degree to which other clients or potential clients use our services. •There is a risk that we may initiate a clinical trial for a client, and then the client becomes unwilling or unable to fund the completion of the clinical trial, and we may be ethically bound to complete or wind down the clinical trial at our own expense. 19 19 19

🟡 Modified We may experience challenges with the acquisition, development, enhancement or deployment of technology necessary for our business. 🔒
🟡 Modified Data protection, privacy and similar laws and regulations in the United States and around the world restrict access, use and disclosure of personal information, and failure to comply with or adapt to changes in these laws could materially and adversely harm our business. 🔒
🟡 Modified We may be affected by healthcare reform and potential additional reforms, which may adversely impact the biopharmaceutical industry and reduce demand for our services or negatively impact our profitability. 🔒
🟡 Modified Environmental events may have an impact on our business. 🔒
🟡 Modified The expectations and requirements of regulators and other key stakeholders on sustainability-related matters, continue to evolve and diverge, and our ability to meet these expectations and requirements could increase our costs, and inaction could harm our reputation and adversely impact our financial results. 🔒
5 more changes in this filing

Full diff access, historical comparisons, and cross-company signal tracking.

Get full access — from $29/month Already a Pro subscriber? View full diff →